跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 44 条关于
“AQP4”
全部
44
临床试验
27
药物
6
机构
0
资讯
11
2个月前
Sleep Habits May Modify How AQP4 Gene Variants Shape Early Alzheimer's Brain Changes
上个月
Obinutuzumab Beta Posts 93.1% Relapse Reduction in AQP4+ NMOSD, Joining a Crowded Efficacy Plateau
3个月前
Obinutuzumab β (MIL62) Shows 93.1% Relapse Risk Reduction in Phase 3 Trial for AQP4-IgG+ NMOSD
去年
New NMOSD Treatment Recommended for PBS Inclusion
去年
Alexion Secures Canadian Access Agreement for Ultomiris in Two Rare Autoimmune Diseases
去年
B Cell Depletion Therapy Shows Promise for NMOSD Treatment Through Comprehensive Immune System Modulation
5个月前
ENSPRYNG Achieves 68% Reduction in MOGAD Relapses in Pivotal Phase III Trial
去年
Amgen's Uplizna Shows Sustained Efficacy in Myasthenia Gravis Patients Through One Year
去年
FDA Approves First Targeted Therapy for IgG4-Related Disease: Amgen's UPLIZNA
9个月前
FDA Approves UPLIZNA as First CD19-Targeted B Cell Therapy for Generalized Myasthenia Gravis
第 1 页,共 2 页
上一页
下一页